Zymergen has purchased Lodo Therapeutics, which is advancing Rockefeller research, for an undisclosed sum five years after the company raised its only funding round.

The GlaxoSmithKline and Celgene-backed immunotherapy developer has revealed its intention to float on the Nasdaq Global Market.

The Pfizer, GlaxoSmithKline, Novartis, AbbVie and Astellas-backed oncology therapy developer is set to go public through a reverse takeover.

SoftBank Vision Fund 2 led the e-commerce holding company's latest round, reportedly the largest series A ever closed by a US-based company.

The payment software provide's shared popped on their first day after an IPO that followed two Goldman Sachs-backed funding rounds.

Alexandria Venture Investments has participated in an $88.9m round which has pushed the biotech developer's total funding past $142m.

Lilly Asia Ventures has returned to back the immuno-oncology therapy developer’s latest round, eight months after participating in the company’s series B.

Shionogi has joined subsidiaries of Merck Group and Amgen in the equity portion of a series D round for the digital therapeutics developer.

UC San Francisco spinout Effector Therapeutics is set to go public through a reverse merger with Locust Walk Acquisition Corp that includes a $60m PIPE financing.

Columbia’s Text IQ has been bought by Relativity for an undisclosed amount.